aibioPharmaCyte Biotech gets Nasdaq minimum bid price deficiency notice, has until June 1, 2026
Tickers PMCB
Nasdaq told PharmaCyte on December 1, 2025 that its stock had failed the $1.00 minimum bid price over 30 consecutive business days. The company has until June 1, 2026, and any reverse stock split would need shareholder approval. The filings give no share price or cash figure to show how far the company is from compliance.
Key facts
- Company
- PharmaCyte Biotech, Inc. (NASDAQ: PMCB)
- News type
- Listings
- Primary source
- PharmaCyte Biotech, Inc. Form 8-K filed December 5, 2025 (SEC EDGAR)
PharmaCyte Biotech, Inc. (Nasdaq: PMCB), a Nevada corporation based in Las Vegas, received a written deficiency notice from Nasdaq on December 1, 2025. The company reported the notice in a Form 8-K dated December 1, 2025 and signed December 5, 2025. The notice says the company no longer meets the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The company has until June 1, 2026 to regain compliance. The notice does not change the listing or trading of the stock today.
What the notice says
The letter came from the Listing Qualifications Department of The Nasdaq Stock Market LLC. It says PharmaCyte is not in compliance with Nasdaq Listing Rule 5550(a)(2), which the 8-K calls the Bid Price Rule. That rule requires a minimum bid price of $1.00 per share. Nasdaq based its finding on the closing bid price over the 30 consecutive business days before the notice. The 8-K does not list those prices or say why the shares fell below $1.00.
The company says the notice does not affect its operations or its reporting obligations with the Securities and Exchange Commission.
The compliance period
Nasdaq gave PharmaCyte 180 calendar days under Nasdaq Listing Rule 5810(c)(3)(A), to a Compliance Date of June 1, 2026. To regain compliance, the closing bid price must be at least $1.00 for a minimum of 10 consecutive business days, or a longer run if Nasdaq staff require one under Rule 5810(c)(3)(H). The 8-K gives no closing price for any day after the notice.
If the deadline passes
The company may be eligible for a second 180-day period if it meets the initial listing requirements of the Capital Market, other than the bid price, and tells Nasdaq in writing that it intends to cure the deficiency. The 8-K says the cure may include a reverse stock split.
If PharmaCyte does not qualify, or does not regain compliance during a second period, Nasdaq will notify it that its securities are subject to delisting. The company would then be entitled to appeal to a Nasdaq Hearings Panel.
What the company says it will do
PharmaCyte says it will actively monitor the closing bid price and consider all options, including a reverse stock split, "subject to stockholder approval." It adds that there can be no assurance it will regain or maintain compliance with the Bid Price Rule or the other continued listing requirements.
The 8-K does not mention a proxy statement, a meeting date or a split ratio. Any reverse split would therefore need a vote that the filing does not yet schedule.
Earlier financing terms
The company's annual report for the year ended April 30, 2025, describes a private placement on May 9, 2023. PharmaCyte sold 35,000 Series B preferred shares at $1,000 each, sold together with warrants. The preferred was initially convertible into up to 8,750,000 common shares at $4.00 per share, and the warrants covered another 8,750,000 shares at $4.00, expiring five years from issuance.
The report says all preferred shares were redeemed as of April 30, 2025, and that no remaining obligations exist. The report's account of the placement does not say whether the warrants remain outstanding, and the 8-K does not address them.
A 2023 investment in Femasys
The same report describes a November 14, 2023 purchase by PharmaCyte of $5,000,000 in senior unsecured convertible notes from Femasys Inc., convertible into Femasys common stock at $1.18 per share. PharmaCyte also received warrants for Femasys shares at $1.18 and $1.475. It may nominate one Femasys director until it owns less than 4.99% of Femasys shares or the notes are repaid.
The report does not say what the stake is worth now, or whether the notes and warrants are still held.
What the filings leave out
The 8-K gives no share count, cash balance or spending figure. The 8-K does not show how long PharmaCyte can fund its operations while it works on the bid price.
Who signed
Chief Executive Officer and President Joshua N. Silverman signed the 8-K on December 5, 2025.